## UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 15, 2015

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

## Aduro Biotech, Inc.

## File No. 333-202667 - CF#31929

\_\_\_\_\_

Aduro Biotech, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the exhibits to a Form S-1 registration statement filed on March 11, 2015.

Based on representations by Aduro Biotech, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.18	through December 19, 2024
Exhibit 10.19	through December 19, 2024
Exhibit 10.20	through December 19, 2024
Exhibit 10.21	through March 2, 2018
Exhibit 10.22	through March 2, 2018
Exhibit 10.23	through March 2, 2025
Exhibit 10.24	through March 2, 2018
Exhibit 10.25	through March 2, 2018
Exhibit 10.26	through March 2, 2018
Exhibit 10.27	through March 2, 2018
Exhibit 10.28	through March 2, 2018
Exhibit 10.29	through March 2, 2018
Exhibit 10.30	through March 2, 2021
Exhibit 10.32	through March 2, 2018
Exhibit 10.34	through April 6, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary